Allogene Therapeutics, Inc. Common Stock (ALLO) Stock Price
ALLOStock
$1.31+3.15%52W
Market Cap$452.59M
P/E—
PEG Ratio—
Div yield—
Beta0.76
ALLO Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-52.45%
Price vs S&P 500 (4W)-21.16%
VGM Score41.50
ALLO Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.15 | -$0.13 | +12.16%(+$0.02) | |
| Q1 2026 | -$0.18 | -$0.18 | +0.00%(+$0.00) | |
| Q4 2025 | -$0.22 | -$0.17 | +22.46%(+$0.05) | |
| Q3 2025 | -$0.23 | -$0.19 | +18.69%(+$0.04) | |
| Q2 2025 | -$0.27 | -$0.22 | +17.23%(+$0.05) |
ALLO Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.20
4.16
4.22
4.22
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
ALLOAllogene Therapeutics, Inc. Common Stock | D | — | C | 97.5x | — | — | — | $1.31 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Allogene Therapeutics, Inc. Common Stock
Allogene Therapeutics is a clinical-stage immuno-oncology company developing off-the-shelf allogeneic CAR T-cell therapies for cancer and autoimmune diseases. Its genetically engineered, donor-derived T-cell products offer broader patient eligibility and manufacturing scalability compared to autologous therapies. The pipeline targets lymphoma, leukemia, solid tumors, and autoimmune disorders, with revenue generated from collaborations and licensing agreements.